Clinical Leader: What Clinical Trial Information Do VCs And Investors Actually Want?

In a crowded biotech startup market, it's essential for investors to identify prospects with potential for their portfolios. Equally important, startup founders need to know what information to present to investors to stand out, demonstrate expertise, and convey value.

In a recent article for Clinical Leader, LongeVC’s Artem Trotsyuk, Sergey Jakimov, Artemy Shumskiy, and Vlad Cernoutan emphasized that VCs and investors seeking to fund biotech and medtech companies are interested in more than just the specifics of the clinical trial itself. They also want to see a strong team with clinical trial experience and a plan for handling unforeseen circumstances. Here are the key things they are looking for:

An experienced team: Investors want to see a team with a proven track record in conducting clinical trials. This includes having people who understand the costs, timelines, and challenges involved.
A clear target market: Investors want to know who the target patient group is and why they were chosen. They also want to understand how this choice will affect the overall market size and go-to-market strategy.
A plan for the future: Investors are interested in what happens after the initial clinical trial. This includes plans for larger trials, potential changes in direction based on results, and how the company will handle challenges like patient recruitment.
A well-designed trial: While investors may not need all the details of the trial design, they do want to know that it is well-designed and considers future regulatory hurdles and potential outcomes.

You can read the full article here.